← Back to patent-cliff list
JMKX-003002
Tier C — Watch / tradeJMKX-003002
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Hyperphosphataemia, End-stage renal disease, Nephropathy
Regional status
US
Phase I
2023-11-09
EU
-
China
Phase II
2024-12-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JMKX-003002?
Approved indications include: Hyperphosphataemia, End-stage renal disease, Nephropathy.
When does the JMKX-003002 patent expire?
No public expiry year is available for JMKX-003002 yet; this page updates once verified.
How do I get a quote for JMKX-003002 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01